Table 2.
Donor and recipient characteristics in patients with moderate and severe steatotic livers who received IFLT versus CLT.
| Variables | IFLT (N = 6) | CLT (N = 20) | P |
|---|---|---|---|
| Preoperative donor parameters | |||
| Donor age, years | 45.00 ± 8.03 | 37.85 ± 2.70 | 0.057 |
| Donor sex male n (%) | 6 | 19 | 0.576 |
| BMI (kg/m2) | 19.66 ± 0.76 | 21.40 ± 0.80 | 0.166 |
| Donor type, DBD | 6 | 19 | 0.576 |
| AST (U/l) | 183.17 ± 63.40 | 80.70 ± 20.17 | 0.058 |
| ALT (U/l) | 82.00 ± 17.76 | 58.65 ± 12.58 | 0.671 |
| GGT (U/l) | 56.67 ± 24.02 | 80.70 ± 20.17 | 0.380 |
| Bilirubin (mmol/l) | 31.70 ± 6.34 | 23.79 ± 4.20 | 0.812 |
| CIT, h | 0 | 7.30 ± 0.47 | 0.009 |
| Donor WIT, min | 0 | 1.00 ± 0.56 | 0.030 |
| ICG % | 5.0 ± 0.9 | 3.0 ± 1.5 | 0.321 |
| Preoperative recipient parameters | |||
| Recipient age, years | 50.83 ± 5.02 | 53.10 ± 2.03 | 0.751 |
| Recipient sex male n (%) | 6 | 19 | 0.576 |
| BMI (kg/m2) | 20.01 ± 1.53 | 21.80 ± 0.77 | 0.877 |
| MELD | 18.83 ± 4.54 | 17.25 ± 2.02 | 0.848 |
| Transplantation parameters | |||
| Intraoperative transfusions (U) | 7.63 ± 1.41 | 7.74 ± 1.88 | 0.094 |
| Blood loss (ml) | 2800.00 ± 331.66 | 2820.00 ± 683.24 | 0.149 |
| Anhepatic time, min | 56.50 ± 11.45 | 58.30 ± 4.51 | 0.197 |
| ICU length‐of‐stay (h) | 28.50 ± 7.92 | 82.02 ± 37.03 | 0.343 |
| Postoperative outcome parameters | |||
| ALT (U/l) | 196.83 ± 62.16 | 869.55 ± 159.45 | 0.133 |
| AST (U/l) | 280.67 ± 80.63 | 2947.90 ± 532.69 | 0.009 |
| GGT (U/l) | 174.83 ± 34.69 | 338.60 ± 56.42 | 0.032 |
| Bilirubin (mmol/l) | 85.47 ± 22.18 | 119.19 ± 31.73 | 0.275 |
| Creatine (mmol/l) | 83.83 ± 10.82 | 172.12 ± 22.14 | 0.024 |
| EAD | 0 | 12 | 0.01 |
| PNF | 0 | 2 | 0.420 |
| Acute kidney injury | 0 | 8 | 0.063 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CIT, cold ischaemia time; CLT, conventional liver transplantation; CLT, conventional liver transplantation; DBCD, donor after brain and cardiac death; DBD, Donor after brain death; DCD, donor after cardiac death; EAD, early allograft dysfunction; GGT, γ‐glutamyl transpeptidase; HCC, hepatocellular carcinoma; ICG, Indocyanine green; ICU, intensive care unit; IFLT, ischaemia‐free liver transplantation; IFLT, ischaemia‐free liver transplantation; MELD, model for end‐stage liver diseases; PNF, primary nonfunction; WIT, warm ischaemia time.